Since Mounjaro became available on the NHS in 2025, it has been one of the most searched questions in the UK. The honest answer is: yes, it is available, but access is tightly restricted, and the vast majority of people who would benefit from it do not currently qualify. Here is a clear breakdown of where things stand, who qualifies, and what your options are if you do not meet the criteria.
The NHS rollout timeline
Mounjaro received NICE approval for weight management in England in December 2024. Rollout happened in two stages.
March 2025: available through specialist NHS weight management services (Tier 3), typically via GP referral with a waiting list.
June 23, 2025: NHS England launched primary care prescribing, meaning GPs in England could begin prescribing Mounjaro directly.
Important caveat: implementation has varied significantly by Integrated Care Board (ICB). A BMJ investigation in January 2026 found one in five local areas still lacked a functional NHS pathway for Mounjaro. If your GP is not yet set up to prescribe, you will need to wait until they are.
Who currently qualifies for NHS Mounjaro?
The NHS is using a phased 12-year approach to reach an estimated 3.4 million eligible patients. Only those with the highest clinical need are being prioritised first.
On the NHS in England, tirzepatide is being introduced in phases. People with a BMI of 40 or more and at least four of five weight-related conditions (high blood pressure, abnormal blood fats, obstructive sleep apnoea, heart disease and type 2 diabetes) could get it first (Cohort 1); from around June 2026 this widened to a BMI of 35 to 39.9 with four conditions, and from around March 2027 it is due to include a BMI of 40 or more with three conditions. Your GP can tell you whether you qualify. For the full criteria, see NHS England's weight management injections page.
Having type 2 diabetes and a BMI of 35 is not sufficient on its own for Cohort 1. NICE estimates that about 3.4 million people in England could be eligible for tirzepatide under its guidance, and expects at least 220,000 of them to be able to get it on the NHS in the first three years.
How does the NHS identify eligible patients?
GP surgeries are proactively identifying eligible patients through medical records and contacting them directly when the prescribing service is ready. Patients should not self-refer. This overwhelms practices and delays the rollout.
If you believe you meet the criteria and have not been contacted, you can ask your GP whether their surgery is participating and whether you appear to be eligible.
NHS Mounjaro vs private Mounjaro
Private eligibility is significantly more accessible, under the MHRA marketing authorisation: BMI ≥30, or BMI ≥27 with at least one weight-related health condition.
Patients who don't meet NHS Cohort 1 criteria can access Mounjaro privately following a clinical consultation. Clinical safety standards, contraindication screening, monitoring, are the same. The medication itself is identical: Mounjaro (tirzepatide) by Eli Lilly, same doses, same KwikPen.
Can I switch from private to NHS?
Not automatically. NHS eligibility is assessed at time of referral based on current BMI and comorbidities, not when private treatment began. If you meet Cohort 1 criteria, discuss with your GP. Your surgery must be set up to prescribe and there may be a wait.